• Advocates worried refugees are being denied rights at Nauru

    A refugee advocacy group has raised the alarm over treatment of a growing number of people transferred to the Nauru detention facility. It comes after the third suspected asylum seeker group in five months was found on WA's Kimberley coastline and sent to the remote Micronesian island. There's concern a historical track record of human rights abuses experienced by detainees is continuing.

  • Korean auto exports hit record $17.5 billion in Q1

    Korean automobile exports reached a record $17.5 billion in the first quarter of this year, marking a 2.7 percent increase from the same period last year, according to the Ministry of Trade, Industry and Energy on Thursday. Automobile exports surged to $6.2 billion in March alone, following a slight dip to $5.2 billion the previous month. This boost was largely driven by the robust performance of hybrid vehicles, whi

  • Korean auto exports hit record $17.5 billion in Q1

    Korean automobile exports reached a record $17.5 billion in the first quarter of this year, marking a 2.7 percent increase from the same period last year, according to the Ministry of Trade, Industry and Energy on Thursday. Automobile exports surged to $6.2 billion in March alone, following a slight dip to $5.2 billion the previous month. This boost was largely driven by the robust performance of hybrid vehicles, whi

  • Singer Park Bo-ram dies, age 30

    Singer Park Bo-ram has died at the age of 30. The singer's agency, Xanadu Entertainment, said that Park Bo-ram died unexpectedly Thursday afternoon. According to the police, Park was with two other women at her acquaintance's house when she was found collapsed and in cardiac arrest. She was moved to the hospital but died at 11:17 p.m., about an hour later. Police are investigating the exact cause of her dea

  • Samsung Bioepis begins phase 3 clinical study for its Keytruda biosimilar

    Samsung Bioepis, Samsung Group’s biosimilar arm, announced Friday that the company had started a phase 3 clinical study for SB27, a Keytruda biosimilar. Keytruda is an immuno-oncology drug developed by MSD, a US multinational pharmaceutical company. Indications for the drug include non-small cell lung cancer (NSCLC), melanoma and neck cancer. According to MSD's earnings release, global sales of Keytruda in